Salivary potassium measured by genetically encoded potassium ion indicators as a surrogate for plasma potassium levels in hemodialysis patients—a proof-of-concept study
- 14 June 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 38 (3), 757-763
- https://doi.org/10.1093/ndt/gfac195
Abstract
Hyperkalemia is a common complication in cardiorenal patients treated with agents interfering with renal potassium (K+) excretion. It frequently leads to discontinuation of potentially life-saving medication, which has increased the importance of K+-monitoring. Non-invasive means to detect hyperkalemia are currently unavailable, but would be of potential use for therapy guidance. The aim of the present study was to assess the analytical performance of genetically-encoded potassium-ion indicators (GEPIIs) in measuring salivary K+ ([K+]Saliva) and to determine whether changes of [K+]Saliva depict those of [K+]Plasma. We conducted this proof-of-concept study: saliva samples from 20 healthy volunteers as well as plasma and saliva from 29 patients on hemodialysis (HD) before and after three consecutive HD treatments were collected. We compared [K+]Saliva as assessed by the gold standard ion-selective electrode (ISE) with GEPII measurements. The Bland-Altmann analysis showed a strong agreement (Bias 0.71; 95% limits of agreement from -2.79 to 4.40) between GEPII and ISE. Before treatment, patients on HD showed significantly higher [K+]Saliva compared to healthy controls (median 37.7 [30.85; 48.46] vs. 23.8 [21.63; 25.23] mmol/L; p < 0.05). [K+]Plasma in HD patients decreased significantly after dialysis. This was paralleled by a significant decrease in [K+]Saliva, and both parameters increased until the subsequent HD session. Despite similar kinetics, we found weak or no correlation between [K+]Plasma and [K+]Saliva. GEPIIs have shown an excellent performance in determining [K+]Saliva. [K+]Plasma and [K+]Saliva exhibited similar kinetics. To determine whether saliva could be a suitable sample type to monitor [K+]Plasma, further testing in future studies are required.Funding Information
- Vifor Pharma
This publication has 18 references indexed in Scilit:
- Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of CardiologyEuropean Heart Journal - Cardiovascular Pharmacotherapy, 2018
- A real-world cohort study on the quality of potassium and creatinine monitoring during initiation of mineralocorticoid receptor antagonists in patients with heart failureEuropean Heart Journal - Quality of Care & Clinical Outcomes, 2018
- Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trialThe Lancet, 2018
- Novel genetically encoded fluorescent probes enable real-time detection of potassium in vitro and in vivoNature Communications, 2017
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2016
- Medically Relevant Assays with a Simple Smartphone and Tablet Based Fluorescence Detection SystemSensors, 2015
- Correlation of Serum and Salivary Biochemical Parameters in end Stage Renal Disease Patients Undergoing Hemodialysis in Pre and Post-Dialysis StateJournal of Clinical and Diagnostic Research, 2014
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureThe New England Journal of Medicine, 2014
- Production of recombinant immunotherapeutics for anticancer treatmentBioengineered, 2013
- Salivary Composition and Calculus Formation in Patients Undergoing HemodialysisThe Journal of Periodontology, 1980